Status:

COMPLETED

Switchover Trial From Imiglucerase to Plant Cell Expressed Recombinant Human Glucocerebrosidase

Lead Sponsor:

Pfizer

Conditions:

Gaucher Disease

Eligibility:

All Genders

2+ years

Phase:

PHASE3

Brief Summary

This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) enzyme...

Detailed Description

This is a multi-center, open-label, switchover trial to assess the safety of taliglucerase alfa in 30 patients with Gaucher disease who are currently being treated with imiglucerase (Cerezyme®) ERT. E...

Eligibility Criteria

Inclusion

  • Males and females, 2 years or older
  • Confirmed diagnosis of Gaucher disease by the enzymatic activity assay
  • Stable Gaucher disease
  • Treatment with imiglucerase (Cerezyme®) for at least 2 years and on a stable maintenance regimen (dose and regimen unchanged, except for situation of drug shortage) for at least the last six months
  • Able to provide written informed consent

Exclusion

  • Currently taking another experimental drug for any condition
  • History of allergy to carrots
  • History of allergy to beta lactam antibiotics
  • Previous infusion reaction suspected to be allergic in nature to Cerezyme® or Ceredase® or receiving premedication to prevent infusion reactions
  • Presence of HIV and/or HBsAg and/or hepatitis C infection
  • Presence of unresolved anemia due to iron, folic acid or vitamin B12 deficiency
  • Presence of any significant comorbidity that could confound the interpretation of the clinical response to taliglucerase alfa
  • Presence of any medical, emotional, behavioral or psychological condition that in the judgment of the Investigator would interfere with the patient's compliance with the requirements of the study

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

May 1 2013

Estimated Enrollment :

31 Patients enrolled

Trial Details

Trial ID

NCT00712348

Start Date

December 1 2008

End Date

May 1 2013

Last Update

October 4 2018

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

University Research Foundation for Lysosomal Storage Diseases, Inc.

Coral Springs, Florida, United States, 33065

2

Department of Human Genetics, Emory University School of Medicine

Decatur, Georgia, United States, 30033

3

Neurogenetics, NYU at Rivergate

New York, New York, United States, 10016

4

Bone Marrow Transplant Service, The Royal Melbourne Hospital

Parkville, Victoria, Australia